Subtopic Deep Dive
Pheochromocytoma Genetic Mutations
Research Guide
What is Pheochromocytoma Genetic Mutations?
Pheochromocytoma genetic mutations are germline and somatic alterations in genes such as SDHB, SDHD, VHL, RET, and FH that drive tumorigenesis in pheochromocytoma and paraganglioma.
Germline mutations in SDHx genes and VHL occur in 20-30% of pheochromocytoma cases, enabling hereditary syndrome identification (Neumann et al., 2002, 1355 citations). SDHB mutations associate with extra-adrenal paragangliomas and higher malignancy risk (Astuti et al., 2001, 1089 citations). Clinical guidelines recommend genetic testing for all patients (Lenders et al., 2014, 2668 citations).
Why It Matters
Genetic mutation profiling stratifies pheochromocytoma patients for metastasis risk, guiding surveillance and therapy in endocrine surgery. SDHB/SDHD mutations predict aggressive tumors, informing familial screening protocols (Astuti et al., 2001; Neumann et al., 2002). VHL and RET testing identifies syndromic cases for targeted management (Amar et al., 2005). Precision medicine reduces recurrence through early intervention, impacting 25% of apparently sporadic cases (Neumann et al., 2002).
Key Research Challenges
Mutation Detection Yield
Systematic screening detects mutations in 25-30% of cases, but yield varies by tumor location and family history (Amar et al., 2005). False negatives occur due to incomplete gene panels. Neumann et al. (2002) showed RET, VHL, SDHD, SDHB mutations in nonsyndromic pheochromocytoma.
Genotype-Phenotype Correlation
SDHB mutations link to metastatic paragangliomas, while SDHD predicts head-neck tumors, complicating risk models (Astuti et al., 2001). Functional impacts of Krebs cycle disruptions remain unclear (Pollard et al., 2005). Clinical translation lags behind genomic findings.
Somatic vs Germline Distinction
Distinguishing somatic from germline mutations requires tumor-normal sequencing, increasing costs. SDHA mutations act as tumor suppressors in paragangliomas (Burnichon et al., 2010). Integration into guidelines needs validation (Lenders et al., 2014).
Essential Papers
Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline
Jacques W.M. Lenders, Quan‐Yang Duh, Graeme Eisenhofer et al. · 2014 · The Journal of Clinical Endocrinology & Metabolism · 2.7K citations
The Task Force recommends that initial biochemical testing for PPGLs should include measurements of plasma free or urinary fractionated metanephrines. Consideration should be given to preanalytical...
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Hartmut P.H. Neumann, Birke Bausch, Sarah R. McWhinney et al. · 2002 · New England Journal of Medicine · 1.4K citations
Almost one fourth of patients with apparently sporadic pheochromocytoma may be carriers of mutations; routine analysis for mutations of RET, VHL, SDHD, and SDHB is indicated to identify pheochromoc...
Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma
Dewi Astuti, Farida Latif, Ashraf Dallol et al. · 2001 · The American Journal of Human Genetics · 1.1K citations
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
Martin Faßnacht, Olaf M. Dekkers, Tobias Else et al. · 2018 · European Journal of Endocrinology · 886 citations
Adrenocortical carcinoma (ACC) is a rare and in most cases steroid hormone-producing tumor with variable prognosis. The purpose of these guidelines is to provide clinicians with best possible evide...
Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations
Patrick J. Pollard, J.-J. Brière, Neyaz Alam et al. · 2005 · Human Molecular Genetics · 838 citations
The nuclear-encoded Krebs cycle enzymes, fumarate hydratase (FH) and succinate dehydrogenase (SDHB, -C and -D), act as tumour suppressors. Germline mutations in FH predispose individuals to leiomyo...
Genetic Testing in Pheochromocytoma or Functional Paraganglioma
Laurence Amar, Jérôme Bertherat, Éric Baudin et al. · 2005 · Journal of Clinical Oncology · 676 citations
Purpose To assess the yield and the clinical value of systematic screening of susceptibility genes for patients with pheochromocytoma (pheo) or functional paraganglioma (pgl). Patients and Methods ...
Primary aldosteronism: renaissance of a syndrome
William F. Young · 2007 · Clinical Endocrinology · 666 citations
Summary Great strides have been made in our understanding of the pathophysiology of primary aldosteronism syndrome since Conn's description of the clinical presentation of a patient with an aldoste...
Reading Guide
Foundational Papers
Read Lenders et al. (2014) first for clinical testing guidelines (2668 citations); Neumann et al. (2002) for nonsyndromic mutation prevalence (1355 citations); Astuti et al. (2001) for SDHB discovery (1089 citations).
Recent Advances
Burnichon et al. (2010) on SDHA as tumor suppressor (647 citations); Lenders et al. (2014) updates integrate SDHx testing.
Core Methods
Genomic sequencing of SDHx/VHL/RET panels; functional assays measure succinate/fumarate accumulation and HIF1α (Pollard et al., 2005); biochemical metanephrine testing pre-genetics (Lenders et al., 2014).
How PapersFlow Helps You Research Pheochromocytoma Genetic Mutations
Discover & Search
Research Agent uses searchPapers on 'SDHB germline mutations pheochromocytoma' to retrieve 50+ papers including Astuti et al. (2001); citationGraph maps connections from Lenders et al. (2014, 2668 citations) to SDHx studies; findSimilarPapers expands to VHL/RET clusters; exaSearch uncovers functional assays.
Analyze & Verify
Analysis Agent applies readPaperContent to Neumann et al. (2002) for mutation prevalence stats; verifyResponse with CoVe cross-checks claims against Amar et al. (2005); runPythonAnalysis parses mutation frequencies from Pollard et al. (2005) tables using pandas for HIF1α correlations; GRADE grading scores evidence from guidelines (Lenders et al., 2014).
Synthesize & Write
Synthesis Agent detects gaps in SDHA paraganglioma research post-Burnichon et al. (2010); flags contradictions in metastasis predictors across Astuti et al. (2001) and Neumann et al. (2002); Writing Agent uses latexEditText for mutation tables, latexSyncCitations for 10+ references, latexCompile for review drafts, exportMermaid for SDHx pathway diagrams.
Use Cases
"Analyze SDHB mutation frequencies in pheochromocytoma cohorts"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas aggregation of cohort data from Astuti et al. 2001 and Amar et al. 2005) → CSV export of prevalence stats.
"Draft LaTeX review on VHL mutations in pheochromocytoma"
Research Agent → citationGraph (Neumann et al. 2002 hub) → Synthesis Agent → gap detection → Writing Agent → latexEditText → latexSyncCitations → latexCompile → PDF with cited sections.
"Find code for SDH mutation functional assays"
Research Agent → paperExtractUrls (Pollard et al. 2005) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for Krebs cycle simulations.
Automated Workflows
Deep Research workflow scans 50+ SDHx papers via searchPapers → citationGraph → structured report on mutation spectra (Astuti et al., 2001). DeepScan applies 7-step CoVe to verify genotype-phenotype links from Neumann et al. (2002), with GRADE checkpoints. Theorizer generates hypotheses on FH/SDH pseudohypoxia from Pollard et al. (2005).
Frequently Asked Questions
What defines pheochromocytoma genetic mutations?
Germline mutations in SDHB, SDHD, VHL, RET, FH drive 20-40% of cases, acting via Krebs cycle disruption or HIF stabilization (Pollard et al., 2005; Neumann et al., 2002).
What methods detect these mutations?
Sanger sequencing and NGS panels screen RET, VHL, SDHx; guidelines recommend for all PPGL patients (Lenders et al., 2014; Amar et al., 2005).
What are key papers?
Lenders et al. (2014, 2668 citations) provides guidelines; Neumann et al. (2002, 1355 citations) shows 25% germline hits; Astuti et al. (2001, 1089 citations) links SDHB to paraganglioma.
What open problems exist?
Somatic-germline distinction needs cheaper assays; genotype-phenotype models for metastasis lack validation beyond SDHB (Burnichon et al., 2010; Astuti et al., 2001).
Research Adrenal and Paraganglionic Tumors with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pheochromocytoma Genetic Mutations with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Adrenal and Paraganglionic Tumors Research Guide